Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaTHway China phase 3 trial of TransCon PTH in adults with hypoparathyroidism
CTR20212047Phase 3Active
- Sponsor
- Ascendis Pharma
- Start
- Dec 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoparathyroidism comparing TransCon PTH with Placebo (2 arms). Primary endpoint: Composite biochemical and treatment-independence response at week 26. Started Dec 2021; status: active.
02
Drugs
palopegteriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on CTR20212047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212047.